Check out this morning’s top movers from around Wall Street, compiled by The Fly.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
HIGHER –
- Verastem (VSTM) up 29% after announcing that the FDA has accepted for review the new drug application under the accelerated approval pathway for avutometinib, an oral RAF/MEK clamp, in combination with defactinib, an oral FAK inhibitor, for the treatment of adult patients with recurrent low-grade serous ovarian cancer
- Acadia Pharmaceuticals (ACAD) up 9% after being selected to join the S&P SmallCap 600 effective prior to the opening of trading on Friday, January 3
UP AFTER EARNINGS/GUIDANCE –
LOWER –
- Sangamo (SGMO) down 55% after a decision by Pfizer (PFE) to terminate the giroctocogene fitelparvovec global collaboration and license agreement between the parties
- Dave (DAVE) down 9% after the Federal Trade Commission has referred its federal court case against Dave Inc. to the U.S. Department of Justice which has filed an amended complaint in the case that names CEO Jason Wilk as a defendant and seeks civil penalties
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VSTM:
- Verastem price target raised to $20 from $13 at BTIG
- 3 Best Stocks to Buy Now, 12/31/2024, According to Top Analysts
- Verastem announces FDA acceptance and Priority Review of NDA for Avutometinib
- Verastem jumps 50% to $5.50 on FDA priority review for Avutometinib
- Verastem price target raised to $9 from $7 at Mizuho